SEARCH SITE
VIRGINIA LAW PORTAL
- Code of Virginia
- Virginia Administrative Code
- Constitution of Virginia
- Charters
- Authorities
- Compacts
- Uncodified Acts
- RIS Users (account required)
SEARCHABLE DATABASES
- Bills & Resolutions
session legislation - Bill Summaries
session summaries - Reports to the General Assembly
House and Senate documents - Legislative Liaisons
State agency contacts
ACROSS SESSIONS
- Subject Index: Since 1995
- Bills & Resolutions: Since 1994
- Summaries: Since 1994
Developed and maintained by the Division of Legislative Automated Systems.
1999 SESSION
HJ 734 Study; therapeutic interchange of chemically dissimilar drugs.
Introduced by: John J. Davies III | all patrons ... notes | add to my profiles
SUMMARY AS PASSED: (all summaries)
Therapeutic interchange of chemically dissimilar drugs. Directs the Joint Commission on Health Care to study the issues relating to the therapeutic interchange of chemically dissimilar drugs. The Joint Commission is directed to collect data on chemically dissimilar drugs which may be interchanged therapeutically to assess the efficacy of this practice; solicit input from experts in pharmacy and chemical composition of drugs and the mechanisms by which drugs work in the human body to treat disease; conduct a literature search for studies of the use of therapeutically dissimilar drugs for the same or similar therapies; receive input from all stakeholders, including, but not limited to, physicians, pharmacists, insurance companies, health maintenance organizations, third-party pharmacy benefit managers, managed care pharmacy organizations, physicians, patients, and manufacturers; examine other states’ laws and regulations to identify possible mechanisms for regulating the practice of therapeutic interchange of chemically dissimilar drugs; conduct a comprehensive review of the related issues at the national level; take such other actions as appears necessary and appropriate to collect sufficient data and analysis of the issues; and make recommendations concerning whether the practice of therapeutic interchange of chemically dissimilar drugs should be regulated; the components of any such regulation, if recommended; definitions of relevant terms; and the appropriate body for such regulation, if recommended.
FULL TEXT
- 01/21/99 House: Presented & ordered printed 999041198 pdf
- 03/23/99 House: Bill text as passed House and Senate (HJ734ER) pdf
HISTORY
- 01/21/99 House: Presented & ordered printed 999041198
- 01/21/99 House: Referred to Committee on Health, Welfare and Institutions
- 01/27/99 House: Assigned to H. W. I. sub-committee: 2
- 01/30/99 House: Reported from H. W. I. (15-Y 7-N)
- 02/04/99 House: Taken up
- 02/04/99 House: Engrossed by House
- 02/04/99 House: Agreed to by House (88-Y 11-N)
- 02/04/99 House: VOTE: ADOPTION (88-Y 11-N)
- 02/04/99 House: Communicated to Senate
- 02/05/99 Senate: Reading waived
- 02/05/99 Senate: Referred to Committee on Rules
- 02/16/99 Senate: Reported from Rules by voice vote
- 02/17/99 Senate: Reading waived (40-Y 0-N)
- 02/17/99 Senate: VOTE: (40-Y 0-N)
- 02/18/99 Senate: Read third time
- 02/18/99 Senate: Agreed to by Senate by voice vote
- 03/23/99 House: Bill text as passed House and Senate (HJ734ER)